Make Your Voice Heard in Patient-Focused Drug Development

An FDA meeting early next month will focus on developing drugs for chronic pain and patient input on the topic will be emphasized. Find out how your voice can be heard in the drug development process.

Regular visitors to MedShadow know that as a nonprofit organization, we strive to make the voice of the patient heard more — not only by doctors, but by regulatory agencies, especially the FDA, as well. So I was pleasantly surprised last week to see the FDA publish a statement from Commissioner Scott Gottlieb dealing with “new agency efforts to advance the patient voice in medical product development and FDA regulatory decision-making.”

Any effort to give patients more of a say in the development of drugs and medical products, as well as regulatory decisions, is a positive. Gottlieb’s statement was quite long, but the crux of his message, as it relates to patients, follows:

“We must continue to reflect on how we can make the science of drug development and review more modern and more patient-centered, so that approved products impact the metrics that real-world patients and families value most. This requires ongoing engagement with the patient community. Done well, the result is more and more of our review of new medical products benefits from a better understanding of the patient’s experience, providing our reviewers with the critically important context of a disease, and helping them to understand what’s most important to patients related to treatment benefits, risks and disease burden.”

I couldn’t agree more. And as Gottlieb mentioned, the FDA has held Patient-Focused Drug Development (PFDD) meetings in over 20 disease areas, such as opioid abuse, HIV, autism and Parkinson’s. Bravo to the agency for holding these meetings. The agency also came out with reports on what they learned from patients; you can read more about it here.

Next Topic: Chronic Pain

The next PFDD meeting is scheduled for July 9 and will focus on chronic pain. The meeting will be webcast, and you can submit comments related to the meeting through September 10. If chronic pain is an issue for you or someone you love and you have something to say, this is your opportunity to have your voice heard.

While it’s fine to have patient meetings to collect patients’ input, the big question is, will drug developers be listening to and incorporating these patient concerns? It’s hard to say. However, the FDA did issue new guidance for stakeholders to do just this. You can take a look at it here if you like.

The bottom line is that the FDA is giving patients more and more input in the drug development process. If there’s a disease area you are concerned with or have strong feelings about, speak up. It could provide valuable insight for a new drug.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement